CACNB3抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P06118(CACNB3 Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

CACNB3 antibodies target the β3 subunit of voltage-gated calcium channels (VGCCs), which are critical for regulating calcium influx in excitable cells. The CACNB3 gene encodes an auxiliary β subunit that modulates the trafficking, membrane localization, and biophysical properties of the pore-forming α1 subunit in L-type (Cav1.x) and other VGCCs. This subunit plays a role in calcium-dependent processes such as muscle contraction, neurotransmitter release, and gene expression.

CACNB3 is expressed in tissues like the brain, heart, and smooth muscle, and its dysfunction has been linked to cardiovascular disorders, neurological conditions, and cancer. Antibodies against CACNB3 are primarily used in research to study its expression patterns, interaction partners, and pathophysiological roles. They are validated in techniques like Western blotting, immunohistochemistry, and immunofluorescence. Some studies explore autoantibodies against CACNB3 in autoimmune contexts, though this is less characterized compared to other VGCC subunits. Commercial CACNB3 antibodies are typically raised in rabbits or mice using recombinant protein fragments or synthetic peptides. Researchers must verify specificity due to potential cross-reactivity with other β subunits (β1. β2. β4) and consider splice variants. These tools contribute to understanding calcium channel biology and diseases like arrhythmias, epilepsy, or hypertension linked to calcium signaling abnormalities.